Delivery Order SPE2DB20D3304-SPE2DB25FW8H8
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Abiroterone Acetate 250 mg tablets (120-count packages) with a ceiling value of $184,749.89. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 22, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,774.15 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120 count) on July 21, 2025, with completion scheduled for July 22, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Abiroterone Acetate 250 mg tablets (120-count) valued at $13,701.92. This firm fixed-price delivery order is classified as non-competitive and will be completed by July 22, 2025. The product will be delivered to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Abiroterone Acetate 250 mg tablets (120-count supply) on September 15, 2025, with a ceiling value of $1,539.02. This competitive, firm fixed-price delivery order is scheduled for ultimate completion by September 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified vendors. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,489.04 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120-count units) under a firm fixed-price contract. This non-competitive delivery order, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $96,898.94 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $31,517.29 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 500 mg tablets (60-count units). This competitive, firm fixed-price contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a standard pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a $46,593.78 delivery order to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 250 mg tablets (120-count) on August 19, 2025, with completion scheduled for August 20, 2025. This competitively awarded, firm fixed price contract has no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on June 17, 2025, for Abiroterone Acetate 500 mg tablets (60-count) with a ceiling value of $17,936.40. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and carries an ultimate completion date of June 18, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,340.06 to AmerisourceBergen Drug Corp for the supply of Abiroterone Acetate 500 mg tablets (60 count) on August 13, 2025, with completion targeted for August 14, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical products will be...
- SPE2DB20D3304Indefinite Delivery Contract
- SPE2DB20D3304-SPE2DB25FW8H8Delivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Abiroterone Acetate 250 mg tablets (120-count) with a ceiling value of $3,276.40. This competitively awarded, non-set-aside delivery order operates under a firm fixed-price structure with an ultimate completion date of August 5, 2025. The contract is being performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a broad portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill complex medical procurement requirements across multiple therapeutic domains. This particular delivery order for Abiroterone Acetate, a hormone therapy medication, reflects the company's ongoing role as a primary pharmaceutical supplier to Defense Health Agency and other federal healthcare systems through the DLA's global pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/4/25 |